quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:00:05·300d
INSIDERFiling
Regulus Therapeutics Inc. logo

Director Collier Kathryn J returned 75,565 shares to the company, closing all direct ownership in the company (SEC Form 4)

RGLS· Regulus Therapeutics Inc.
Health Care
Original source

Companies

  • RGLS
    Regulus Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 27UpdateWells Fargo$6.00
  • Aug 2UpdateOppenheimer$7.00
  • Mar 18UpdateLeerink Partners$6.00
  • Sep 2UpdateCantor Fitzgerald$2.00

Related

  • SEC291d
    SEC Form 15-12G filed by Regulus Therapeutics Inc.
  • SEC296d
    SEC Form EFFECT filed by Regulus Therapeutics Inc.
  • SEC296d
    SEC Form EFFECT filed by Regulus Therapeutics Inc.
  • SEC296d
    SEC Form EFFECT filed by Regulus Therapeutics Inc.
  • SEC296d
    SEC Form EFFECT filed by Regulus Therapeutics Inc.
  • SEC296d
    SEC Form EFFECT filed by Regulus Therapeutics Inc.
  • SEC296d
    SEC Form EFFECT filed by Regulus Therapeutics Inc.
  • SEC296d
    SEC Form EFFECT filed by Regulus Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022